Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.36−0.30 (-18.07%)
Close on Nov 17, 2026Market cap $16.99MP/E –Yield –
Aligos Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Aligos Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -2031.1%. For fiscal 2025 it was -1106.7%, against -3633.6% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1106.7% | +2526.9 |
| FY2024 | Dec 31, 2024 | -3633.6% | −2217.4 |
| FY2023 | Dec 31, 2023 | -1416.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -814.1% | −14668.8 |
| Q4 FY2025 | Dec 31, 2025 | -11763.9% | +1792.2 |
| Q3 FY2025 | Sep 30, 2025 | -4256.0% | −2715.3 |
| Q2 FY2025 | Jun 30, 2025 | -1643.8% | −2120.8 |
| Q1 FY2025 | Mar 31, 2025 | 13854.7% | +18878.1 |
| Q4 FY2024 | Dec 31, 2024 | -13556.1% | −9405.5 |
| Q3 FY2024 | Sep 30, 2024 | -1540.7% | +122.0 |
| Q2 FY2024 | Jun 30, 2024 | 477.0% | +914.6 |
| Q1 FY2024 | Mar 31, 2024 | -5023.5% | +11372.9 |
| Q4 FY2023 | Dec 31, 2023 | -4150.6% | – |
| Q3 FY2023 | Sep 30, 2023 | -1662.8% | – |
| Q2 FY2023 | Jun 30, 2023 | -437.6% | – |
| Q1 FY2023 | Mar 31, 2023 | -16396.4% | – |
See a number that looks wrong?